KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena Inc., the leader in G-protein coupled receptor (GPCR) biased ligand drug discovery, today announced the initiation of a Phase 2a clinical trial with its lead program, TRV120027, a beta-arrestin biased angiotensin II type 1 receptor (AT1R) ligand, the first biased ligand designed to treat patients with acute heart failure (AHF).
